IL150129A0 - Polypeptide compositions with improved stability - Google Patents

Polypeptide compositions with improved stability

Info

Publication number
IL150129A0
IL150129A0 IL15012900A IL15012900A IL150129A0 IL 150129 A0 IL150129 A0 IL 150129A0 IL 15012900 A IL15012900 A IL 15012900A IL 15012900 A IL15012900 A IL 15012900A IL 150129 A0 IL150129 A0 IL 150129A0
Authority
IL
Israel
Prior art keywords
glycerin
compositions
polypeptide
chemical stability
improved stability
Prior art date
Application number
IL15012900A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27341882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL150129(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP37720899A external-priority patent/JP2001181203A/ja
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL150129A0 publication Critical patent/IL150129A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15012900A 1999-12-16 2000-12-05 Polypeptide compositions with improved stability IL150129A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17113599P 1999-12-16 1999-12-16
JP37720899A JP2001181203A (ja) 1999-12-16 1999-12-28 安定性が改良されたポリペプチド組成物
US18103000P 2000-02-08 2000-02-08
PCT/US2000/032421 WO2001043762A2 (en) 1999-12-16 2000-12-05 Polypeptide compositions with improved stability

Publications (1)

Publication Number Publication Date
IL150129A0 true IL150129A0 (en) 2002-12-01

Family

ID=27341882

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15012900A IL150129A0 (en) 1999-12-16 2000-12-05 Polypeptide compositions with improved stability

Country Status (15)

Country Link
EP (1) EP1242121B1 (de)
JP (1) JP2003523972A (de)
CN (1) CN1409640A (de)
AT (1) ATE288765T1 (de)
AU (1) AU777570B2 (de)
BR (1) BR0016334A (de)
CA (1) CA2394213A1 (de)
DE (2) DE60018105T2 (de)
DK (1) DK200000375U1 (de)
EA (1) EA004631B1 (de)
ES (1) ES2236010T3 (de)
IL (1) IL150129A0 (de)
PL (1) PL355378A1 (de)
PT (1) PT1242121E (de)
WO (1) WO2001043762A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20040121009A1 (en) * 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
AU2003301654A1 (en) * 2002-10-22 2004-05-13 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
PL1772446T3 (pl) 2003-11-20 2011-03-31 Solvay Proces wytwarzania związków organicznych z gliceryny, pochodzącej z surowców odnawialnych
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
PL1789434T3 (pl) 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
DK1884507T3 (da) * 2006-07-27 2010-08-16 Cognis Ip Man Gmbh Fremgangsmåde til fremstilling af glycerol
TWI478875B (zh) 2008-01-31 2015-04-01 Solvay 使水性組成物中之有機物質降解之方法
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
FR2935968B1 (fr) 2008-09-12 2010-09-10 Solvay Procede pour la purification de chlorure d'hydrogene
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102596175A (zh) 2009-07-06 2012-07-18 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
DK2433651T3 (da) 2010-09-03 2013-04-08 Aug Hedinger Gmbh & Co Kg Fremgangsmåde til bestemmelse af aldehyder og ketoner i glycerin
CN107759771A (zh) 2010-09-30 2018-03-06 索尔维公司 天然来源的环氧氯丙烷的衍生物
US9097692B2 (en) 2010-10-01 2015-08-04 Aug. Hedinger Gmbh & Co. Kg Method for quantitatively determining impurities in glycerin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
EP3229828B1 (de) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物
CN120112503A (zh) * 2022-10-13 2025-06-06 阿彻丹尼尔斯米德兰德公司 肠胃外药物应用中作为赋形剂的甘油的纯化
IT202300020130A1 (it) 2023-09-29 2025-03-29 Ibsa Inst Biochimique Sa Formulazioni farmaceutiche stabili di amminoacidi, peptidi o proteine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9709845B1 (pt) * 1996-06-20 2008-11-18 preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.

Also Published As

Publication number Publication date
CN1409640A (zh) 2003-04-09
EP1242121B1 (de) 2005-02-09
EP1242121A2 (de) 2002-09-25
BR0016334A (pt) 2002-09-10
CA2394213A1 (en) 2001-06-21
ES2236010T3 (es) 2005-07-16
WO2001043762A3 (en) 2002-01-10
WO2001043762A2 (en) 2001-06-21
DK200000375U1 (da) 2001-03-16
EA004631B1 (ru) 2004-06-24
EA200200684A1 (ru) 2003-02-27
ATE288765T1 (de) 2005-02-15
JP2003523972A (ja) 2003-08-12
PL355378A1 (en) 2004-04-19
DE60018105D1 (de) 2005-03-17
AU2049301A (en) 2001-06-25
AU777570B2 (en) 2004-10-21
DE60018105T2 (de) 2005-12-29
DE20021079U1 (de) 2001-03-22
PT1242121E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
IL150129A0 (en) Polypeptide compositions with improved stability
GB0013488D0 (en) Chemical compound
EP0695171A1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
DE60132498D1 (en) Isoprenoidproduktion
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
MY133969A (en) Indoloquinazolinones
WO2002018572A3 (en) Membrane penetrating peptides and uses thereof
AU2002228650A1 (en) Gas dehydration using membrane and potassium formate solution
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
CA2278365A1 (en) Alcohols as lubricity additives for distillate fuels
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
GB9920908D0 (en) Chalcone coumarins
AU7914600A (en) The use of baclofen in the treatment of alcohol withdrawal syndrome and to promote alcohol abstinence in alcoholics
AU5690400A (en) Novel compounds
MXPA03004539A (es) Luciferasas aisladas y uso de las mismas.
UA42797C2 (uk) Похідні хінолон- і нафтиридонкарбонової кислоти та похідні ізоіндолу для їх одержання
WO2002029104A8 (en) Tumor marker and methods of use
AU2002210533A1 (en) Identification of cytotoxic activity from the ink of aplysia punctata
AU2001218083A1 (en) Ace inhibitor-vasopressin antagonist combinations
NZ516605A (en) Novel anti-allergic agents
WO2001070384A3 (de) Verwendung von duftalkoholalkoxylaten als solubilisierhilfsmittel
WO2000000509A3 (en) Peptides for inhibiting hpv e7 proteins
UA30876A (uk) Спирт етиловий ректифікований "пшенична сльоза"
TR200102815T1 (tr) Displazili dokunun tespiti için kullanılacak in vivo lekeleme bileşik ve metodları.
TAJIMA Peter Mcnamara: Political Economy and Statesmanship: Smith, Hamilton and the Foundation of the Commercial Republic, Northern University Press, 1998, 191p.